Tigatuzumab

From WikiMD.org
Jump to navigation Jump to search

Tigatuzumab

Tigatuzumab (pronounced tee-ga-too-zoo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of immunotherapy that targets the death receptor 5 (DR5) on the surface of cancer cells.

Etymology

The name "Tigatuzumab" is derived from the scientific nomenclature for therapeutic antibodies, where "-tuzumab" indicates a humanized antibody. The prefix "Tiga-" is likely a proprietary designation by the drug's developer.

Mechanism of Action

Tigatuzumab works by binding to the DR5 receptor on cancer cells, which triggers a process called apoptosis, or programmed cell death. This is a natural process that the body uses to remove old or damaged cells, but in the case of cancer, this process is often disrupted. By triggering apoptosis, Tigatuzumab can help to control the growth and spread of cancer cells.

Clinical Trials

Tigatuzumab has been studied in several clinical trials for its potential use in treating various types of cancer, including colorectal cancer, non-small cell lung cancer, and breast cancer. However, as of now, it has not been approved by the Food and Drug Administration (FDA) for use in the United States.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski